Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles
AssigneesUniversity of Cincinnati, North Carolina Agricultural and Technical State University
InventorsLaura Conforti, Yeoheung Yun
Life of this patent
Estimating the term…
Abstract
Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout siRNA, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of T cells by selectively targeting memory T cells with the nanoparticles, which deliver their siRNA cargo into the cytosol of the TM cell thus reducing ion channel expression and decreasing Ca2+ influx.
Claims12
A method of treating a patient suffering from a condition of the immune system characterized by overexpressed and/or hyperexcitable T-cells, the method comprising administering to the patient a composition formulated to selectively bind to a CD45RO-positive isoform of the T-cells and transfect it with siRNA, the composition comprising:
- lipid nanovesicles functionalized with surface-bound antibody selective for a membrane protein unique to the CD45RO-positive isoform;
- and siRNA effective for inhibiting expression of a Kv1.3 ion channel of the CD45RO-positive isoform cells upon transfection, said siRNA encapsulated within the lipid nanovesicle and comprising one or more Kv1.3-specific siRNA.
A method of treating a patient suffering from chronic systemic lupus erythematosus, the method comprising:
- administering to the patient a composition comprising lipid nanovesicles surface-functionalized with anti-CD45LRO and encapsulating Kv1.3-specific siRNA.
Dependencies are inferred from the claim text.